Actuate Therapeutics, Inc. Investment Income, Interest
Actuate Therapeutics, Inc. (ACTU) reported Investment Income, Interest of $45.02 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Income Statement › Other Income
us-gaap:InvestmentIncomeInterest · last filed 2026-08-14
- Actuate Therapeutics, Inc. investment income, interest for the quarter ending 2026-06-30 was $45.02K, a 83.48% increase year-over-year.
- Actuate Therapeutics, Inc. investment income, interest for the quarter ending 2026-03-31 was $85.27K, a 59.02% increase year-over-year.
- Actuate Therapeutics, Inc. investment income, interest for the quarter ending 2025-12-31 was $139.58K, a 18.17% increase year-over-year.
- Actuate Therapeutics, Inc. investment income, interest for the quarter ending 2025-09-30 was $69.97K, a 13.35% decline year-over-year.
- Actuate Therapeutics, Inc. investment income, interest for fiscal 2025 was $287.71K, a 29.43% increase from fiscal 2024.
- Actuate Therapeutics, Inc. investment income, interest for fiscal 2024 was $222.29K, a 36.97% decline from fiscal 2023.
- Actuate Therapeutics, Inc. investment income, interest for fiscal 2023 was $352.67K.
| Period end | Investment Income, Interest 3 month | Investment Income, Interest 6 month | Investment Income, Interest 9 month | Investment Income, Interest 12 month |
|---|---|---|---|---|
| 2026-06-30 | $45.02K 10-Q · filed 2026-08-14 | $130.28K 10-Q · filed 2026-08-14 | $269.87K derived: sum of 3 quarters · filed 2026-08-14 | $339.84K derived: sum of 4 quarters · filed 2026-08-14 |
| 2026-03-31 | $85.27K 10-Q · filed 2026-05-14 | $224.85K derived: sum of 2 quarters · filed 2026-05-14 | $294.82K derived: sum of 3 quarters · filed 2026-05-14 | $319.36K derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-12-31 | $139.58K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-26 | $209.55K derived: sum of 2 quarters · filed 2026-03-26 | $234.09K derived: sum of 3 quarters · filed 2026-08-14 | $287.71K 10-K · filed 2026-03-26 |
| 2025-09-30 | $69.97K 10-Q · filed 2025-11-13 | $94.50K derived: sum of 2 quarters · filed 2026-08-14 | $148.13K 10-Q · filed 2025-11-13 | $266.24K derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-06-30 | $24.53K 10-Q · filed 2026-08-14 | $78.16K 10-Q · filed 2026-08-14 | $196.27K derived: sum of 3 quarters · filed 2026-08-14 | $277.02K derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-03-31 | $53.62K 10-Q · filed 2026-05-14 | $171.74K derived: sum of 2 quarters · filed 2026-05-14 | $252.49K derived: sum of 3 quarters · filed 2026-05-14 | $261.13K derived: sum of 4 quarters · filed 2026-05-14 |
| 2024-12-31 | $118.11K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-26 | $198.86K derived: sum of 2 quarters · filed 2026-03-26 | $207.51K derived: sum of 3 quarters · filed 2026-03-26 | $222.29K 10-K · filed 2026-03-26 |
| 2024-09-30 | $80.75K 10-Q · filed 2025-11-13 | $89.39K derived: sum of 2 quarters · filed 2025-11-13 | $104.18K 10-Q · filed 2025-11-13 | $163.87K derived: sum of 4 quarters · filed 2025-11-13 |
| 2024-06-30 | $8.64K 10-Q · filed 2025-08-14 | $23.43K 10-Q · filed 2025-08-14 | $83.12K derived: sum of 3 quarters · filed 2025-08-14 | $209.06K derived: sum of 4 quarters · filed 2025-08-14 |
| 2024-03-31 | $14.79K 10-Q · filed 2025-05-15 | $74.47K derived: sum of 2 quarters · filed 2025-05-15 | $200.42K derived: sum of 3 quarters · filed 2025-05-15 | |
| 2023-12-31 | $59.69K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-13 | $185.63K derived: sum of 2 quarters · filed 2025-03-13 | $352.67K 10-K · filed 2025-03-13 | |
| 2023-09-30 | $125.94K 10-Q · filed 2024-11-13 | $292.98K 10-Q · filed 2024-11-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Anebulo Pharmaceuticals, Inc. (ANEB) | United States | $0.015B | |
| Tvardi Therapeutics, Inc. (TVRD) | United States | $0.014B | |
| Vyome Holdings, Inc (HIND) | United States | $0.014B | -1.38 |
| Lantern Pharma Inc. (LTRN) | United States | $0.015B | -2.87 |
| Citius Pharmaceuticals, Inc. (CTXR) | United States | $0.016B | -133.06 |
| BullFrog AI Holdings, Inc. (BFRG) | United States | $0.014B | |
| Korsana Biosciences, Inc. (CYCN) | United States | $0.016B | |
| LISATA THERAPEUTICS, INC. (LSTA) | United States | $0.014B | -2.13 |
| Vistagen Therapeutics, Inc. (VTGN) | United States | $0.013B | -0.14 |
| MUSTANG BIO, INC. (MBIO) | United States | $0.013B |